Rationale for Correct Answer

The correct answer is: Tepotinib

Two targeted therapies are FDA approved for treatment of advanced NSCLC harboring a MET exon 14 skipping mutation: tepotinib and capmatinib.1 These therapies are National Comprehensive Cancer Network (NCCN)-preferred first line therapies for MET exon 14-mutated disease. Another therapy, crizotinib, is recommended in the NCCN guidelines as useful for first-line use in certain circumstances.2 Alectinib and brigatinib are FDA approved therapies for ALK-positive advanced NSCLC only.1 Cabozantinib is not an FDA approved therapy for NSCLC but is considered useful in certain circumstances for patients with RET-positive disease according to NCCN guidelines.1,2

1. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. Updated April 13, 2023. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450